The effects of HER2 monoclonal antibody in women with HER2-overexpressing metastatic breast cancer

被引：0
|
作者：
Boer R.
机构：
来源：
Breast Cancer Research | / 1卷 / 1期
关键词：
HER-2; Metastatic breast cancer; Monoclonal antibody;
D O I：
10.1186/bcr-1999-66610
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
相关论文
共 50 条
  • [1] The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer
    Dent, S.
    Verma, Sh.
    Latreille, J.
    Rayson, D.
    Clemons, M.
    Mackey, J.
    Verma, Su
    Lemieux, J.
    Provencher, L.
    Chia, S.
    Wang, B.
    Pritchard, K.
    CURRENT ONCOLOGY, 2009, 16 (04) : 235 - 245
  • [2] Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
    Shak, S
    SEMINARS IN ONCOLOGY, 1999, 26 (04) : 71 - 77
  • [3] Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer
    Labidi, Soumaya
    Mejri, Nesrine
    Lagha, Aymen
    Daoud, Nouha
    El Benna, Houda
    Afrit, Mehdi
    Boussen, Hamouda
    BREAST CARE, 2016, 11 (06) : 418 - 422
  • [4] A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody
    Ohta, M
    Tokuda, Y
    Suzuki, Y
    Kubota, M
    Watanabe, T
    Fujii, H
    Sasaki, Y
    Niwa, T
    Makuuchi, H
    Tajima, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (11) : 553 - 556
  • [5] HER2 overexpressing metastatic breast cancer.
    Spigel D.R.
    Burstein H.J.
    Current Treatment Options in Oncology, 2002, 3 (2) : 163 - 174
  • [6] Mechanisms of Action and Biological Significance of HER2 Mutations in HER2-Overexpressing Breast Cancer
    Boulbes, D. R.
    Jin, Q.
    Arold, S. T.
    Ladbury, J. E.
    Yu, D.
    Esteva, F. J.
    CANCER RESEARCH, 2011, 71
  • [7] Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
    Burstein, HJ
    Kuter, I
    Campos, SM
    Gelman, RS
    Tribou, L
    Parker, LM
    Manola, J
    Younger, J
    Matulonis, U
    Bunnell, CA
    Partridge, AH
    Richardson, PG
    Clarke, K
    Shulman, LN
    Winer, EP
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2722 - 2730
  • [8] Treatment of HER2-overexpressing breast cancer
    Baselga, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 36 - 40
  • [9] Effects of trastuzumab and paclitaxel in HER2-overexpressing breast cancer
    Li, Songhua
    Higuchi, Hideo
    Ohuchi, Noriaki
    FUTURE MEDICAL ENGINEERING BASED ON BIONANOTECHNOLOGY, PROCEEDINGS, 2006, : 395 - +
  • [10] A phase I study of a first-in-class HER2 antibody-drug conjugate in patients with HER2-overexpressing metastatic breast cancer.
    Burris, H. A.
    Krop, I. E.
    Modi, S.
    Rodon, J.
    Lutzker, S. G.
    Holden, S. N.
    Bhattacharya, S.
    Sliwkowski, M. X.
    Beeram, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S104 - S104
12345